MiddleEast and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market,by Drug Type (Steroid, Immunoglobulins, Thrombopoietin Receptor Agonist andOthers, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies andOnline Pharmacies), and By Country (Turkey, Israel, Egypt, Saudi Arabia, UAE,and Rest of Middle East) was valued at US$ 82.23 million in 2019, and is projected to exhibit a CAGR of 4.0% overthe forecast period (2019 - 2027), as highlighted in a new report published byCoherent Market Insights.
Increasing number of clinicaltrials, rising government support and healthcare spending for development ofbetter medical facilities in the Middle East are the major factors that areexpected to drive growth of the Middle East and Turkey immune ThrombocytopenicPurpura (ITP) Treatment Drugs Market. Various organizations are focusing ondeveloping new solutions for treatment of immune thrombocytopenic purpura whichis expected to favor growth of the Middle East and Turkey immuneThrombocytopenic Purpura (ITP) Treatment Drugs Market. For instance, inNovember 2018, Novartis Pharmaceuticals started a clinical trial to study theability of Eltrombopag to induce sustained treatment-free remission in ITPsubjects who relapsed or failed to respond to initial steroids treatment. It isan interventional clinical trial with more than 100 participants. The clinicaltrial is in phase 2 and is expected to complete in May 2022.
Furthermore, launch of newhealthcare plans and programs is expected to fuel growth of the Middle East andTurkey immune thrombocytopenic purpura drugs market. For instance, in 2010, UAEVision 2021 was launched by the Prime Minister of the U.A.E. As part of theVision 2021 plan, UAE is aiming to provide 'world class healthcare' in the UAEby pushing for greater preventive measures to counter lifestyle-relateddiseases and rare diseases by implementing an accelerated drug registrationsystem, and including health as a key sector within the country's widerinnovation strategy.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3171
Increasing healthcare expenditurein the UAE is expected to boost the market growth over the forecast period. Forinstance, according to the Export Gov., 2019 report, UAE’s healthcareexpenditure was US$ 13.7 billion in 2018, and it is expected to reach US$ 18.3billion by 2023. Furthermore, in 2015, the UAE government launched a new healthinsurance scheme in Dubai. Under this scheme 130,000 people get healthcare at23 private hospitals, and more than 500 medical clinics in and around Dubai.
Browse 20 Market Data Tables and21 Figures spread through 114 Pages and in-depth TOC on "Middle East andTurkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Drug Type(Steroid, Immunoglobulins, Thrombopoietin Receptor Agonist and Others, ByDistribution Channel (Hospital Pharmacies, Retail Pharmacies and OnlinePharmacies), and By Country (Turkey, Israel, Egypt, Saudi Arabia, UAE, and Restof Middle East) - Global Forecast to 2027."
Moreover, many pharmaceuticalcompanies are focusing on entering the Middle East region, which is a highlyuntapped region. For instance, in March 2018, Felix Pharmaceuticals Industriesannounced the construction of a pharmaceutical plant and logistics center atthe Salalah Free Zone in Oman. The company invested US$ 365 million forconstruction of the plant. The project is implemented in three stages, startingin 2018 and ending in 2021.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/middle-east-and-turkey-immune-thrombocytopenic-purpura-treatment-drugs-market-3171
Key Takeaways of the Middle Eastand Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market:
The Middle East and Turkey immuneThrombocytopenic Purpura (ITP) Treatment Drugs Market is expected to expand ata CAGR of 4.0% during the forecast period (2019–2027) owing to increasinggovernment support, clinical trials, and healthcare expenditure.
Among drug type, the steroidsegment is expected to hold major revenue share in 2027. Various organizationsare focusing on R&D activities to develop immune thrombocytopenic purpuradrugs. Ongoing research has analyzed the efficacy and safety of high-dosedexamethasone and prednisone for treatment of patients who have been newlydiagnosed with ITP. The corticosteroid drug has not received approval in any ofthe Middle East countries for treating ITP.
Major players operating in theMiddle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment DrugsMarket include Amgen Inc., Octapharma AG, Novartis AG, Swedish Orphan BiovitrumAB, and Rigel Pharmaceuticals, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3171
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
